# EDGAR Filing Document

**Accession Number:** 0001555280
**File Stem:** 0001555280-26-000029
**Filing Date:** 2026-5
**Character Count:** 9934
**Document Hash:** 5e5592ae478490b8e76a317581808dd9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001555280-26-000029.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001555280-26-000029

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260520

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260522

**DATE AS OF CHANGE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zoetis Inc.
- **CENTRAL INDEX KEY:** 0001555280
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 460696167
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35797
- **FILM NUMBER:** 261010452

**BUSINESS ADDRESS:**
- **STREET 1:** 10 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** 973-822-7000

**MAIL ADDRESS:**
- **STREET 1:** 10 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

?xml version='1.0' encoding='ASCII'? zts-20260520

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

| | |
|:---|:---|
| **FORM** | **8-K** |

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): May 20, 2026** 

---

| |
|:---|
| **Zoetis Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35797** | **46-0696167** |
| (State or other jurisdiction | (Commission File | (I.R.S. Employer |
| of incorporation) | Number) | Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **10 Sylvan Way** | **Parsippany** | **New Jersey** | **07054** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

**(973) 822-7000**

(Registrant's telephone number, including area code)

Not Applicable <br> (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.01 per share** | **ZTS** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the "Company"), prior to the Company's 2026 Annual Meeting of Shareholders (the "Annual Meeting") in accordance with the Company's director retirement policy.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

As discussed under Item 5.02 of this Current Report on Form 8-K, on May 20, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company's shareholders voted on five proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2026 (the "Proxy Statement"). There were 379,034,516 shares of common stock present at the Annual Meeting in person or by proxy, which represented 90.13% of the voting power of the shares of common stock entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote for each share held as of the close of business on March 27, 2026 (the "Record Date").

The shareholders of the Company voted on the following proposals at the Annual Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;1. To elect twelve directors, each to serve for a one-year term until the 2027 Annual Meeting of Shareholders or until each director's successor has been elected and qualified, or until such director's earlier death, resignation or removal.

&nbsp;&nbsp;&nbsp;&nbsp;2. A non-binding advisory vote on the compensation program for the Company's named executive officers, as disclosed in the Proxy Statement.

&nbsp;&nbsp;&nbsp;&nbsp;3. A non-binding advisory vote on the frequency of future advisory votes on the compensation program for the Company's named executive officers, as disclosed in the Proxy Statement.

&nbsp;&nbsp;&nbsp;&nbsp;4. To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;5. To approve a shareholder proposal to permit shareholder action by written consent.

The voting results for each of these proposals are detailed below.

***1. Election of Directors***

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| Paul M. Bisaro | 344648102 | 13423613 | 498498 | 20464303 |
| Vanessa Broadhurst | 347969047 | 9893259 | 707907 | 20464303 |
| Frank A. D'Amelio | 334228663 | 23843344 | 498206 | 20464303 |
| Gavin D.K. Hattersley | 340392396 | 17679615 | 498202 | 20464303 |
| Sanjay Khosla | 341507953 | 16564532 | 497728 | 20464303 |
| Antoinette R. Leatherberry | 354536226 | 3535040 | 498947 | 20464303 |
| Michael B. McCallister | 339555621 | 18514932 | 499660 | 20464303 |
| Gregory Norden | 330178693 | 27889986 | 501534 | 20464303 |
| Kristin C. Peck | 353091387 | 4991721 | 487105 | 20464303 |
| Willie M. Reed | 344480091 | 13582521 | 507601 | 20464303 |
| Mark Stetter | 354854878 | 3221395 | 493940 | 20464303 |
| Stephanie Tilenius | 355556444 | 2521991 | 491778 | 20464303 |

---

Each of the twelve nominees for director was elected to serve for a one-year term until the 2027 Annual Meeting of Shareholders or until each director's successor has been elected and qualified, or until such director's earlier death, resignation or removal.

***2. Advisory Vote on Executive Compensation***

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 306,328,992 | 51,638,692 | 602,529 | 20,464,303 |

---

The shareholders approved, on a non-binding advisory basis, the compensation program for the Company's named executive officers, as disclosed in the Proxy Statement.

------

***3. Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation***

---

| | | | | |
|:---|:---|:---|:---|:---|
| **One Year** | **Two Years** | **Three Years** | **Abstentions** | **Broker Non-Votes** |
| 353402319 | 427780 | 4211897 | 528217 | 20464303 |

---

The shareholders approved, on a non-binding advisory basis, to hold a non-binding advisory vote on the compensation program for the Company's named executive officers every year.

Consistent with the preferences expressed by the Company's shareholders at the Annual Meeting and the recommendation of the Company's Board of Directors, the Company will continue to hold a non-binding advisory vote on the compensation program for the Company's named executive officers every year.

***4. Ratification of Appointment of Independent Registered Public Accounting Firm***

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 367,031,759 | 11,450,123 | 552,634 | 0 |

---

The shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

***5. Shareholder Proposal***

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 167,308,882 | 190,220,865 | 1,040,466 | 20,464,303 |

---

The shareholders did not approve the shareholder proposal to permit shareholder action by written consent.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **ZOETIS INC.** | **ZOETIS INC.** |
| Dated: May 21, 2026 | By: | /s/ Roxanne Lagano |
|  |  | Roxanne Lagano |
|  |  | Executive Vice President, |
|  |  | General Counsel and Corporate Secretary |

---